TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Direct Angioplasty for Non ST Elevation Acute Coronary Events: DANCE Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria Patients presenting with symptoms (onset of symptoms ≤ 12 hours) of a suspected acute coronary syndrome (unstable angina or MI without persistent ST elevation) characterised as follows~* Clinical history consistent with ongoing ischaemic chest pain and/or symptoms AND~* \>1mm ST depression AND/OR ≥2mm T wave inversion in at least two adjacent ECG leads Pathological T wave inversion in leads 1+4 suggesting 'LAD Syndrome' Or Ischaemic ST depression/T wave inversion not fulfilling the above criteria that is felt in the opinion of the attending physician to represent an acute coronary syndrome. AND~* Written informed consent Main exclusion criteria~  1. ≤ 18 years of age~ 2. Previous Coronary Artery Bypass Grafting surgery~ 3. ST elevation myocardial infarction~ 4. Left bundle branch block (LBBB)~ 5. ST depression seen in patients during paced mode only~ 6. Heart rate ≥ 150bpm~ 7. Cardiogenic shock or other catastrophic state~ 8. If in the opinion of the physician the patient is not suitable for revascularisation due to co-morbidity~ 9. Patient participating in another clinical trial such that randomisation to DANCE would result in deviation from the protocol stipulations of either trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Group (Type: EXPERIMENTAL): Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- Percutaneous Coronary Intervention PCI between 24 to 48 hours from randomisation according to local policy and guidelines
- Immediate Invasive Group (Type: ACTIVE_COMPARATOR): Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting Percutaneous Coronary Intervention(PCI) will be performed according to local policy and guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening, including ileal, colonic, or ileo-colonic disease distribution~* Must have had an inadequate response, loss of response, or intolerance to 1 or more of the standard treatments~* Must have active moderate to severe CD~* Men and women must agree to follow specific methods of contraception, if applicable~Exclusion Criteria:~* Severe or fulminant colitis that is likely to require surgery or hospitalization~* Presence of a diagnosis of alternative forms of colitis (infectious, inflammatory including ulcerative colitis, malignant, toxic, indeterminate, etc.) other than Crohn's Disease~* Previous exposure to BMS-986165 in any study~* Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, psychiatric, or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the participant~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BMS-986165 Dose 1 (Type: EXPERIMENTAL): None
- BMS-986165 Dose 2 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Joint Symptoms in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. BC patients with a confirmed diagnosis of hormone receptor-positive BC at the stage of I, II or IIIa;~2. Patients who have completed taxane-based chemotherapy and are currently undergoing hormone treatments for at least three months;~3. Patients indicate ongoing joint symptoms, including joint pain and/or stiffness, at one or more sites of body;~4. Patients started to experience the joint symptoms after the commencement of the hormone treatments;~5. Patients indicate the intensity of their worst pain during the past seven days of greater than 4 points at a 0-10 NRS scale where 0 represents no pain and 10 indicates most severe pain;~6. Patients have at least a primary school education and are able to communicate in Chinese Mandarin or Sichuanese; and~7. Patients agree to participate in the trial and are willing to give written informed consent.~Exclusion Criteria:~1. Patients who had needle phobia and a low count of platelet of less than 50,000;~2. Patients with conditions which are not appropriate for acupuncture including pregnancy, bleeding disorders, local or systematic inflammation, and other neuropathic and/or metabolic problems of the joints;~3. Patients who had received joint surgery or had bone fracture during the past six months;~4. Patients who had received any types of acupoint stimulation (e.g. body acupuncture or acupressure and auricular therapy) during the past six months; and~5. Patients are currently treated with narcotic analgesia or steroids.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- True Acupuncture (Type: EXPERIMENTAL): Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints. Bilateral acupoints will be stimulated including Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
- Sham Acupuncture (Type: SHAM_COMPARATOR): In addition to the routine methods of care, patients allocated to the sham control group will receive sham acupuncture treatment at sham acupoints with superficial needling
- Standard Control Group (Type: NO_INTERVENTION): The third arm will be a standard care control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Postsurgical Bupivacaine Extended-release Liposome Injection for Open-reduction Internal Distal Radius Fixation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Isolated distal radius fracture~Exclusion Criteria:~* No Access to a telephone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Group (Type: ACTIVE_COMPARATOR): Group that receives actual liposomal bupivacaine injections
- Placebo Group (Type: PLACEBO_COMPARATOR): Group that receives placebo injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Minimally Invasive Surgery in Treating Patients With Spinal Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of primary, secondary or metastatic spine tumor and be undergoing any posterior spinal fusion with or without anterior fusion anywhere from occiput to sacrum~* Greater than 3 month life expectancy~* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately~* All subjects must have the ability to understand and the willingness to sign a written informed consent~Exclusion Criteria:~* Patients who are not surgical candidates for spine tumor removal, determined by the surgical team~* Patients who have undergone previous spine surgery for tumor removal will be excluded~* Patients with renal cell carcinoma~* As there is an emphasis on blood loss and length of surgery, the critical variable for homogeneity is the vascularity of the tumor; hypervascular spine tumors are regarded by surgeons as amongst the most challenging of cases; by far the three most common hypervascular metastatic tumors are those arising from renal cell carcinoma, thyroid carcinoma and melanoma; these pathologies are usually regarded as a distinct subset for this reason in the majority of studies; because we rarely encounter the later two pathologies in our practice, we chose to include only the former; however, to further homogenize our study population we will exclude all three of the known hypervascular metastatic spine tumors~* Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (posterior spinal tumor resection) (Type: EXPERIMENTAL): Patients undergo posterior spinal tumor resection on day 0.
- Arm II (anterior and posterior spinal tumor resection) (Type: EXPERIMENTAL): Patients undergo anterior and posterior tumor resection on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Men and non-pregnant women, at least 18 years of age~* Antiretroviral treatment-naïve; defined as no current or previous exposure to \> 1 week of an antiretroviral drug~* Plasma HIV-1 RNA ≥ 1000 copies/mL~* CD4 T-cell count \> 200 cells/mm3~Exclusion Criteria:~* Resistance or partial resistance to any study drug determined by tests at Screening~* Current or historical genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to EFV, TDF, FTC, Protease Inhibitors~* Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV)~* Blood tests that indicate normal liver function~* Hemoglobin \< 8.0 g/dL, platelets \< 50,000 cells/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: BMS-955176 60 mg + TDF/FTC (Type: EXPERIMENTAL): BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
- Arm 2: BMS-955176 120 mg + TDF/FTC (Type: EXPERIMENTAL): BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
- Arm 3: BMS-955176 180 mg + TDF/FTC (Type: EXPERIMENTAL): BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
- Arm 4: EFV + TDF/FTC (Type: ACTIVE_COMPARATOR): BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Thai menopausal women aged between 50-70 years who visit Rajavithi gynecology OPD with informed consent with good communication in the Thai language.~Exclusion Criteria:~* Have acute vulvovaginitis (vaginal swab for wet smear and KOH)~* Patients who have used hormonal replacement therapy within 12 months~* Patients with a history of smoking~* Patients who have used vaginal lubricant or moisturizer~* Patients with an allergic history of oxytocin or gel components~* Morbid obesity BMI \> 30 kg/m2~* Patients who have used vitamin E supplement~* Patients who unable to perform per vaginal examination

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Oxytocin gel (Type: EXPERIMENTAL): Oxytocin gel 400IU per 1 ml (on HPMC 4,000 cps base gel), applied at vaginal canal 1 ml per day for 8 weeks
- Placebo gel (Type: PLACEBO_COMPARATOR): Placebo gel (HPMC 4,000 cps base gel) , applied at vaginal canal 1 ml per day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Medication Histories Conducted by Nurses (RNs), Pharmacy Techs (CPhTs) & Pharmacists (RPhs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted as inpatients from the Emergency Department~Exclusion Criteria:~* Prisoners (because the IRB does not have a prisoner representative)~* Patients not admitted as inpatients through the Emergency Department~* Patients admitted more than once during the study period

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Derangements in Acute Heart Failure Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult (age \> 18 yrs) patients admitted to the Heart Failure Intensive Care Unit (H22) with Acute Heart Failure Syndrome (AHFS) requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.~Exclusion Criteria:~* History of Congenital Heart Disease.~* Acute HF in the setting of acute myocardial infarction.~* Severe Anemia~* Patients listed for cardiac transplantation.~* Terminal Malignancy, AIDS or CNS disease.~* Concomitant sepsis, ARDS, trauma, aortic dissection, or pericardial tamponade

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation (Type: None): Adult (age \> 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have histologically confirmed adenocarcinoma of the prostate, with biopsies obtained within 12 months of registration~  * Gleason score 3+3 or 3+4~ * PSA \<10 ng/mL within 3 months of enrollment~ * Clinical stage T1a-T2a by digital rectal exam~ * Up to 2 intraprostatic nodules visible on MRI, with combined volume \<50% of the total prostate volume~* Karnofsky Performance Status (KPS) \>70%.~* Life expectancy \>10 years~* Age ≥ 19 years~* Subjects given written informed consent~Exclusion Criteria:~* \>2 MRI defined nodules representing prostate cancer~* Total volume of MRI nodules exceeding 50% of total prostate volume~* Positive biopsy core in sextant region without MRI defined nodule (i.e. biopsy proven MRI occult prostate cancer)~* American Urological Association (AUA) urinary score ≥ 18.~* History of inflammatory bowel disease.~* Prior pelvic surgery~* Prior treatment for prostate cancer~* Patients using immunosuppressive medications or other medications that may increase radiation toxicity such as methotrexate, sirolimus, tacrolimus, or colchicine that are unable to discontinue these medications during SBRT course. Use of corticosteroids is not considered an exclusion criteria.~* Platelet count \< 70,000/µL~* Patients unable to discontinue anti-platelet or anti-coagulant medicine such as clopidogrel, dabigatran, warfarin, or low molecular weight heparin. Use of aspirin is not an exclusion criteria.~* Contraindication to MRI such as implanted devices.~* Metallic pelvic implants resulting in imaging artifact within the prostate on MRI or CT

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Focal SBRT with intra-urethral radiotransponder (Type: EXPERIMENTAL): This study will enroll patients that have a confirmed histology of prostate cancer. They will undergo a 3T MRI scan as well as a CT simulation with 16 French Foley Catheter containing dummy beacons for treatment planning purposes. The patient will then receive focal stereotactic body radiotherapy (SBRT) at a dose of 40 gy in 5 total fractions. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent, if required~* Patient received at least 1 dose of moxetumomab pasudotox-tdfk and has completed or discontinued the treatment~* Patient has a medical record available from the start of first dose of moxetumomab pasudotox tdfk~AND at least 1 of the following:~* Patient is ≥65 years old at the time of starting initial treatment with moxetumomab pasudotox-tdfk OR~* Adult (≥18 years old) patient has moderate renal impairment, at the time of starting initial treatment with moxetumomab pasudotox-tdfk

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \<48 hours of age,~* 30 - 36 weeks gestational age at birth based on best estimate using obstetrical sonography (first or second trimester), solid dating criteria, or Ballard examination,~* Birth weight of ≥ 1,000 g,~* 5 minute Apgar score ≥5,~* Requiring nasal cannula O2 \> 1 liter per minute (LPM), continuous positive pressure (CPAP), or non invasive positive pressure ventilation (NIPPV) for treatment of respiratory failure,~* Requiring a fraction of inspired oxygen (FIO2) of at least 0.25 to maintain arterial oxygen saturation (SaO2) 88-94%,~* Parent or guardian has signed informed consent and agrees to all study- related procedures, including those required after hospital discharge.~Exclusion Criteria:~* Major congenital anomaly~* Intubation and surfactant in the delivery room or prior to enrollment in the Neonatal Intensive Care Unit (NICU). Excludes intubation for suctioning.~* Known congenital infection (bacterial, viral),~* Perinatal asphyxia (5 minute Apgar \<5, umbilical artery pH \< 7.0 or evidence of neonatal encephalopathy),~* Mother and/or infant is enrolled in another clinical trial (excluding observational) or has received an investigational drug,~* Has undergone or is anticipated to require a major surgical procedure within the first 48 h of life,~* Any condition which could preclude receiving study drug or performing any study-related procedures,~* Use of postnatal corticosteroids,~* Parent or guardian is unable or unwilling to complete study procedures after hospital discharge.

- Gender: ALL
- Minimum Age: 30 Weeks
- Maximum Age: 36 Weeks
- Healthy Volunteers: f

Study Arms:
- inhaled Nitric Oxide (Type: EXPERIMENTAL): iNO to start at 20 parts per million (ppm) for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
- Nitrogen Gas (Type: PLACEBO_COMPARATOR): Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues